Advertisement

International Urology and Nephrology

, Volume 51, Issue 4, pp 699–705 | Cite as

Pentoxifylline for the prevention of contrast-induced nephropathy in diabetic patients undergoing angioplasty: a randomized controlled trial

  • Naser Aslanabadi
  • Roghayeh Afsar Gharebagh
  • Saba Moharramzadeh
  • Taher Entezari-MalekiEmail author
Nephrology - Original Paper
  • 47 Downloads

Abstract

Objectives

Contrast-induced nephropathy (CIN) is one of the most important complications of contrast media. We aimed to evaluate the preventive effects of pentoxifylline (PTX) on CIN in diabetic patients undergoing angioplasty using cystatin C.

Materials and methods

The present study was a randomized clinical trial, which was investigated the impact of PTX in the prevention of CIN among 90 diabetic patients undergoing the angioplasty using cystatin C as a novel biomarker of renal injury. The patients randomly were allocated 1:1 into the intervention and the control groups. The intervention group received a total of 1200 mg PTX orally before the angioplasty. The serum level of cystatin C and creatinine was measured at baseline and 24 h after the procedure.

Results

The incidence of CIN was 8.9% in the PTX group vs. 6.7% in the control group (p = 1.00). The baseline level of cystatin C was 1.31 ± 0.39 mg/L in the PTX group and 1.24 ± 0.42 mg/L in the control group (p = 0.561). After angioplasty, the level of cystatin C was increased to 1.33 ± 0.61 in PTX group and to 1.31 ± 0.47 in the control group but was not statistically significant. The similar pattern was also seen in the level of serum creatinine.

Conclusions

The results of this study did not support the potential benefit of PTX in the prevention of CIN in diabetic patients undergoing angioplasty.

Keywords

Angioplasty Contrast-induced nephropathy (CIN) Pentoxifylline Diabetes 

Notes

Acknowledgements

The authors would like to thank the Cardiovascular Research Center of Shahid Madani, Tabriz University of Medical Sciences (Tabriz, Iran), for support of the investigation.

Funding

This study was granted by the Cardiovascular Research Center of Shahid Madani, Tabriz University of Medical Sciences (Tabriz, Iran).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Rundback JH, Nah D, Yoo V (2011) Contrast-induced nephropathy. J Vasc Surg 54(2):575–579.  https://doi.org/10.1016/j.jvs.2011.04.047. (Epub 2011 Jul 13)CrossRefGoogle Scholar
  2. 2.
    Bartorelli AL, Marenzi G (2008) Contrast-induced nephropathy. J Interv Cardiol 21(1):74–85. (Epub 2007 Dec 12)CrossRefGoogle Scholar
  3. 3.
    Zhang M, Xu Y-J, Mengi SA, Arneja AS, Dhalla NS (2004) Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. Exp Clin Cardiol 9(2):103–111PubMedCentralGoogle Scholar
  4. 4.
    Ward A, Clissold SP (1987) Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34:50–97CrossRefGoogle Scholar
  5. 5.
    Müller R, Lebrach F (1979) Haemorheological role of platelet aggregation and hypercoagulability in microcirculation: therapeutical approach with pentoxifylline. Pharmatherapeutica 2(6):372–379Google Scholar
  6. 6.
    Dauber IM, Lesnefsky EJ, Ashmore RC et al (1992) Coronary vascular injury due to ischemia-reperfusion is reduced by pentoxifylline. J Pharmacol Exp Ther 260(3):1250–1256Google Scholar
  7. 7.
    Bhat VB, Madyastha KM (2001) Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. Biochem Biophys Res Commun 288(5):1212–1217CrossRefGoogle Scholar
  8. 8.
    Freitas JP, Filipe P, Guerra-Rodrigo F (1995) Potential antioxidative effects of pentoxifylline. CRSeances Soc Biol Fil 189(3):401–405Google Scholar
  9. 9.
    Freitas JP, Filipe PM (1995) Pentoxifylline: a hydroxyl radical scavenger. Biol Trace Elem Res 47(1–3):307–311CrossRefGoogle Scholar
  10. 10.
    Horvath B, Marton Z, Halmosi R, Alexy T, Szapary L, Vekasi J, Biro Z, Habon T, Kesmarky G, Toth K (2002) In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin Neuropharmacol 25(1):37–42CrossRefGoogle Scholar
  11. 11.
    Dávila-Esqueda ME, Martínez-Morales F (2004) Pentoxifylline diminishes the oxidative damage to renal tissue induced by streptozotocin in the rat. Exp Diabesity Res 5:245–251CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Gale SC, Hokama JY, Ritter LS et al (2001) Pentoxifylline reduces coronary leukocyte accumulation early in reperfusion after cold ischemia. Ann Thorac Surg 71(4):1305–1311CrossRefGoogle Scholar
  13. 13.
    Adams JG, Dhar A, Shukla SD, Silver D (1995) Effect of pentoxifylline on tissue injury and platelet-activating factor production during ischemia-reperfusion injury. J Vascul Surg 21(5):742–749CrossRefGoogle Scholar
  14. 14.
    Sener G, Akgun U, Satiroglu H et al (2001) The effect of pentoxifylline on intestinal ischemia/reperfusion injury. Fundam Clin Pharmacol 15(1):19–22CrossRefGoogle Scholar
  15. 15.
    Lechleitner P, Genser N, Mair J et al (1992) Pentoxifylline influences acute-phase response in acute myocardial infarction. J Mol Med 70(9):755Google Scholar
  16. 16.
    Krawczeski CD, Vandevoorde RG, Kathman T, Bennett MR, Woo JG, Wang Y, Griffiths RE, Devarajan P (2010) Serum cystatin C is an early predictive biomarker of acute kidney injury after pediatric cardiopulmonary bypass. Clin J Am Soc Nephrol 5(9):1552–1557CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Yong Z, Pei X, Zhu B, Yuan H, Zhao W (2017) Predictive value of serum cystatin C for acute kidney injury in adults: a meta-analysis of prospective cohort trials. Sci Rep 7:41012CrossRefPubMedCentralGoogle Scholar
  18. 18.
    World Medical Association Declaration of Helsinki (2013) Ethical principles for medical research involving human subjects. World Medical Association. JAMA 310:2191–2194Google Scholar
  19. 19.
    Rahman MM, Haque HS, Banerjee SK, Ahsan SA, Rahman MF, Mahmood M, Salman M, Azam MG (2010) Contrast induced nephropathy in diabetic and non-diabetic patients during coronary angiogram and angioplasty. Mymensingh Med J 19:372–376Google Scholar
  20. 20.
    Yavari V, Ostovan MA, Kojuri J et al (2014) The preventive effect of pentoxifylline on contrast-induced nephropathy: a randomized clinical trial. Int Urol Nephrol 46:41–46CrossRefGoogle Scholar
  21. 21.
    Firouzi A, Eshraghi A, Shakerian F et al (2012) Efficacy of pentoxifylline in prevention of contrast-induced nephropathy in angioplasty patients. Int Urol Nephrol 44:1145–1149CrossRefGoogle Scholar
  22. 22.
    Eshraghi A, Naranji-Sani R, Pourzand H et al (2016) Pentoxifylline and prevention of contrast-induced nephropathy: is it efficient in patients with myocardial infarction undergoing coronary angioplasty? ARYA Atheroscler 12:238–242PubMedCentralGoogle Scholar
  23. 23.
    Dharnidharka VR, Kwon C, Stevens G (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40:221–226CrossRefGoogle Scholar
  24. 24.
    Bachorzewska-Gajewska H, Malyszko J, Sitniewska E et al (2008) NGAL (neutrophil gelatinase-associated lipocalin) and cystatin C: are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine? Int J Cardiol 127(2):290–291CrossRefGoogle Scholar
  25. 25.
    O’Seaghdha CM, Tin A, Yang Q, Katz R, Liu Y, Harris T et al (2014) Association of a cystatin C gene variant with cystatin C levels, CKD, and risk of incident cardiovascular disease and mortality. Am J Kidney Dis 63:16–22CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Cardiovascular Research CenterTabriz University of Medical SciencesTabrizIran
  2. 2.Department of Clinical Pharmacy, Faculty of Pharmacy, Drug Applied Research CenterTabriz University of Medical SciencesTabrizIran

Personalised recommendations